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ntimicrobial  resistance  of Pseudomonas  aeruginosa
n a  Romanian  hospital  at the  dawn  of multidrug
and meropenem. Except for ceftazidime and piperacillin-
tazobactam for which the trend was continuously increasing,esistance
ear Editor,
seudomonas aeruginosa is a clinical and epidemiological
igniﬁcant pathogen involved especially in infections in hos-
italized patients, with an increasing antimicrobial resistance
ver the past few years. Till recently, Romania’s involvement
n antimicrobial surveillance networks was weak.1 Therefore,
e conducted a study in order to determine the antimicro-
ial resistance of P. aeruginosa isolated from various clinical
pecimens.
We analyzed the antimicrobial susceptibility proﬁles of
96 P. aeruginosa strains isolated from patients hospitalized in
Prof. Dr. Matei Bals” National Institute of Infectious Diseases
n Bucharest, Romania, between July 1st 2008 and June 30th
Table 1 – Antimicrobial resistance of Pseudomonas aeruginosa st
Antibiotic n resistant (%) n resistant (%) n resistant (%) 
CEF 156
(53.06%)
38
(49.35%)
53
(52.21%)
PIP-TAZ 142
(49.65%)
30
(39.47%)
50
(53.19%)
IMI  146
(49.8%)
34
(44.15%)
52
(53.61%)
MER 105
(50.48%)
22
(46.81%)
36
(52.17%)
GEN 185
(64.23%)
43
(55.84%)
66
(68.75%)
TOB 140
(50.17%)
32
(42.10%)
52
(54.16%)
AMK 127/271
(46.86%)
23/67
(34.33%)
45/85
(52.94%)
CIP 176/292
(60.27%)
41/77
(53.24%)
64/97
(65.98%)
COL 13/133
(9.77%)
3/15
(20%)
7/32
(21.87%)
T1 (July 1st 2008–December 31st 2008), T2 (January 1st 2009–June 30th 200
30th 2010), CEF, ceftazidime; PIP/TAZ, piperacillin-tazobactam; IMI, imipe
amikacin; CIP, ciproﬂoxacin; COL, colistin.2010. We analyzed the dynamics of the resistance between
four semesters.
The overall resistance rates were: colistin 9.77%, amikacin
46.86%, imipenem 49.8%, piperacillin/tazobactam 49.65%,
meropenem 50.48%, tobramycin 50.17%, ceftazidime 53.06%,
ciproﬂoxacin 60.27%, and gentamicin 64.23%.
The analysis of the temporal evolution of P. aerugi-
nosa resistance to antimicrobials is illustrated in Table 1.
The resistance rates increased between the initial and
the ﬁnal semester for all the antibiotics, but colistinrains.
n resistant (%) n resistant (%) p-Value (T1–T4)
33
(47.67%)
26
(52.38%)
↑
0.6
31
(53.45%)
31
(53.45%)
↑
0.11
34
(55.73%)
26
(44.82%)
↑
1
27
(55.44%)
20
(44.44%)
↓
0.83
36
(63.16%)
40
(68.96%)
↑
0.15
27
(52.94%)
29
(51.78%)
↑
0.29
32/62
(51.61%)
27/57
(47.37%)
↑
0.14
39/63
(61.9%)
32/55
(58.18%)
↑
0
1/44
(2.27%)
3/42
(7.14%)
↓
0.17
9), T3 (July 1st 2009–December 31st 2009), T4 (January 1st 2010–June
nem; MER, meropenem; GEN, gentamicin; TOB, tobramycin; AMK,
for all the other antibiotics the evolution of the resistance
was undulating. None of these trends were statistically
i s . 2 0
r
1
2510  b r a z j i n f e c t d 
signiﬁcant between the initial and the ﬁnal semester of the
study.
Among the three representatives of the aminoglycosides
class, amikacin proved to be superior to gentamicin. We
did not ﬁnd any statistically signiﬁcant differences between
tobramycin and amikacin, or between tobramycin and gen-
tamicin.
The comparative analysis for each time frame regarding
the efﬁciency of antipseudomonal betalactams did not
reveal any statistical signiﬁcance between resistance rates of
ceftazidime versus piperacillin/tazobactam, ceftazidim ver-
sus imipenem/meropenem, piperacillin-tazobactam versus
imipenem/meropenem.
With a good activity, colistin remains the salvage therapy
for P. aeruginosa infections.
A total of 161 strains of P. aeruginosa (54.39%) were resis-
tant to at least three of the antimicrobial groups among
piperacillin-tazobactam, ceftazidime, aminoglycosides, ﬂuo-
roquinolones, carbapenems, and colistin.
Following this study, the ﬁrst attempt to introduce an
antimicrobial stewardship programme was made in our hospi-
tal in 2010. In addition, regional therapeutic recommendations
previously made on rational criteria were modiﬁed in relation
to the resistance problems described and the need for limiting
the negative evolutionary trends on bacterial susceptibility to
antibiotics.2
This study emphasizes that P. aeruginosa isolates are
becoming increasingly resistant to antibiotics in our coun-
try, leaving clinicians with very limited treatment options for
these infections. With such high resistance rates to all the
antipseudomonal antibiotic classes, including carbapenems,
only colistin seems to be a safe treatment option for infections
in which this etiology is suspected.In our country it is imperative to continuously monitor
the antimicrobial resistance patterns as well as to introduce
antimicrobial stewardship programs in order to limit the rising
resistance rates and the spread of these resistant isolates. 1 6;2  0(5):509–510
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